This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution
Annals of Hematology Open Access 15 February 2023
-
Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes
Scientific Reports Open Access 14 February 2023
-
Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients
Bone Marrow Transplantation Open Access 04 October 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

References
Churpek JE, Pyrtel K, Kanchi K-L, Shao J, Koboldt D, Miller CA, et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015;126:2484–90.
Guidugli L, Johnson AK, Alkorta-Aranburu G, Nelakuditi V, Arndt K, Churpek JE, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017;31:1226–9.
Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica. 2016;101:1343–50.
Peterson LC, Bloomfield CD, Niemeyer CM, Döhner HGL. Myeloid neoplasms with germline predisposition. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th ed) Lyon, IARC. 2017.
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Ghemlas I, Li H, Zlateska B, Klaassen R, Fernandez CV, Yanofsky RA, et al. Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes. J Med Genet. 2015;52:575–84.
Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun. 2017;8:1557.
Wlodarski MW, Hirabayashi S, Pastor V, Starý J, Hasle H, Masetti R, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127:1387–97.
Sébert M, Passet M, Raimbault A, Rahmé R, Raffoux E, Sicre de Fontbrune F, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134:1441–4.
Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102:1683–90.
Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Cancer. 2007;109:1536–42.
Trottier AM, Druhan LJ, Kraft IL, Lance A, Feurstein S, Helgeson M, et al. Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Adv. 2020;4:5269–84.
Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125:591–9.
Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transpl. 2011;46:98–104.
Ebens CL, MacMillan ML, Wagner JE. Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. Expert Rev Hematol 2017;10:81–97.
Acknowledgements
The authors would like to gratefully acknowledge all of the individuals who participated in this study and their physicians for submitting the clinical samples. We would also like to thank Michelle Le Beau and Ludmila Hill from the Cancer Cytogenetics Laboratory at The University of Chicago for providing viably frozen bone marrow samples. This study was supported by the Cancer Research Foundation and the Taub Foundation (L.A.G.), the intramural ‘Baustein’ program for Junior Scientists of the Medical Faculty of Ulm University, Ulm, Germany (S.F.), and the German Bundesministerium für Bildung und Forschung ‘MyPred’ (01GM1911B) (B.S., G.G.) and ‘ADDRess’ (01GM1909A) (G.G.) and the Cancer Society of Finland, the Children’s Cancer Foundation Väre, and the Sigrid Juselius Foundation (M.H., O.K., U.W-K.). In addition, the NIH supported this work through: P30CA016056 (use of Roswell Park Comprehensive Cancer Center’s Hematologic Procurement Shared Resource, E.W.), R03HL145253 (J.E.C.), R35CA197458 and R24DK099808 (M-C.K., T.W., S.G., M.L.). We would also like to acknowledge the input of Linda Lutgen-Dunckley, Brandon Martens, and Joseph Moberg from the Roswell Park Hematologic Procurement Shared Resource (CIC 98-05) for providing samples supported by the Cancer Center Support Grant at Roswell Park (2P30CA016056-42). M-C.K. is an American Cancer Society Professor.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We declare the following conflicts of interest: TW consults for Color Genomics. TH is part owner of the Munich Leukemia Laboratory. EAG has received honoraria/advisory board payments from Alexion Pharmaceuticals, Celgene/BMS, AbbVie, and Novartis. EAG has also received institutional research funding from Genentech Inc., Appelis pharmaceuticals, Celldex Therapeutics, and Celgene/BMS. CO has received honoraria/advisory board payments from AbbVie, AstraZeneca, Janssen, Roche, and Novartis. LAG and JEC have received honoraria from UptoDate, Inc. LAG has received advisory board payments from Invitae, Inc.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Feurstein, S., Churpek, J.E., Walsh, T. et al. Germline variants drive myelodysplastic syndrome in young adults. Leukemia 35, 2439–2444 (2021). https://doi.org/10.1038/s41375-021-01137-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01137-0
This article is cited by
-
Impact of gene alterations on clinical outcome in young adults with myelodysplastic syndromes
Scientific Reports (2023)
-
Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients
Bone Marrow Transplantation (2023)
-
ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution
Annals of Hematology (2023)
-
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia
Leukemia (2022)
-
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer
Leukemia (2021)